Key Takeaways AbbVie stock is up 22.5% in 2025, beating its industry, sector and the S&P 500 index.Strong sales of Skyrizi and Rinvoq are replacing Humira and driving top-line growth.Acquisitions in immunology, oncology and neuroscience strengthen AbbVie's pipeline.AbbVie (ABBV) has gained 22.5% so far this year against a decrease of 0.1% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.ABBV Stock Outperforms Industry, Sector & S&P 500Image Sourc ...